Apatinib Monotherapy Versus Apatinib Combined With Camrelizumab for Third-line Treatment of Metastatic Gastric Cancer
Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
This open, single-center, randomized phase II study was to evaluate the clinical benefit of
apatinib plus camrelizumab which is an anti-Programmed cell death-1 (PD-1) monoclonal
antibody, versus apatinib in patients with metastatic gastric cancer refractory to two or
more lines of treatment, fully evaluating the efficacy and safety of the combined regimen.